IDO1 and cancer: Collectively, these results suggest that 11C-l-1MTrp PET imaging can serve as a robust tool to gauge the cancer-immune set point and predict the antitumor immune efficacy of different types of immunotherapeutic blockade in addition to combination immunotherapy targeting multiple factors by monitoring IDO1 expression in the MLNs.